Schizophrenia is a severe psychiatric disorder characterized by psychotic symptoms and functional impairment, with recurrent relapses and continuing disability. The risk factors for schizophrenia are indicators currently perceived as epiphenomena of pathophysiological processes resulting from geneenvironment interactions that remain poorly understood 1 . Widespread impairments in brain function and structure have been shown in schizophrenia cases. It is also clear that, to a lesser degree, unaffected family members share many of the neurobiological abnormalities found in affected individuals, which suggests that the alleles that underlie the genetic risk of schizophrenia may primarily exert their effects on intermediate traits such as cerebral structure or function 
might occur at specific stages of development of occurrences of this disorder 1 . Genetic epidemiological investigations have suggested that there is a genetic component with significant participation in the etiology of schizophrenia, and heritability estimates as high as 80% have been reported 1 . The mode of inheritance is complex, with polygenic environmental interaction. The role of single relevant genes must be small, and therefore association studies involving case-control approaches have been conducted to evaluate the allelic variations of specific candidate genes that may be related to the etiopathology of the disorder 1 . Some of the most investigated genes in studies on vulnerability to schizophrenia are those that code for proteins of the dopaminergic system, because of evidence of the role of central dopamine pathways in the pathophysiology of the disorder. Therefore, the genes involved in the dopaminergic system are potential targets for genetic association investigations in schizophrenia. Polymorphisms in dopamine transporter and receptors genes have been widely investigated as risk factors for schizophrenia development, but the results have been inconclusive [2] [3] [4] [5] . Thus, other possible candidates for such investigations are the enzymes that metabolize dopamine, such as catechol-O-methyltransferase (COMT).
The gene encoding the enzyme COMT has been considered to be a likely candidate for an association with schizophrenia. Most COMT genetic association studies have focused on a particular single nucleotide polymorphism (SNP) that results in a change from valine to methionine at codon 158/108 (rs4680). It has been suggested that this may contribute towards increased prefrontal catabolism and impaired prefrontal cortex function 6 . Another interesting polymorphism of the COMT gene is rs165599 (A/G), which is located in the 3' untranslated region of the COMT gene, close to exon 1. Its G allele was first shown to be highly associated with schizophrenia in Ashkenazi Jews by Shifman et al., as a component of a haplotype (G-G-G haplotype of three SNPs: rs737865, rs4680 and rs165599) of the COMT gene 7 . This haplotype has also been reported to be linked with lower expression of COMT mRNA in the human brain 7 . In a postmortem study, Bray et al. demonstrated that this polymorphism altered COMT gene expression, which was less expressed when the G allele was present 8 . On the other hand, Okochi et al. conducted a meta-analysis study in which no clear association between COMT genotypes and schizophrenia was found 9 . However, some studies have found associations between rs165599 (A/G) COMT genetic polymorphism and different clinical aspects of schizophrenia. Gu et al. showed an association between the polymorphism investigated and violent behavior in a sample of Chinese male schizophrenic patients 10 . In a study conducted on a Taiwanese sample, the A allele of rs165599 COMT polymorphism was transmitted preferentially to the affected individuals, and was significantly associated with later age of onset, greater severity of the delusion/hallucination symptom dimension and poorer performance of neurocognitive functioning 11 . Studying tardive dyskinesia, in a sample of schizophrenia/schizoaffective disorder patients, Zai et al. found a significant association between the marker rs165599 in the 3' untranslated region of COMT and this clinical condition 12 . Thus, since schizophrenia is a mental disorder with different clinical phenotypes, and despite the negative findings from meta-analyses that investigated the association between rs165599 catechol-O-methyltransferase genetic polymorphism and schizophrenia, several studies have found associations of this polymorphism with different clinical features of the disorder.
Taking this into account, we conducted a study with the aims of investigating a possible association between A/G COMT polymorphism in the non-coding region 3' (rs165599) and schizophrenia, and also investigating different aspects of the disorder, such as schizophrenia subtypes and gender. We also examined whether there was any association between homozygosity of the polymorphism investigated and schizophrenia.
METHODS

Sample
The sample was composed of 245 Brazilian patients diagnosed with schizophrenia and 834 sex and age-matched control subjects recruited at the Institute of Psychiatry, University of São Paulo Medical School. Schizophrenia was diagnosed in accordance with the DSM-IV criteria, based on clinical interviews conducted by psychiatrists. The 834 healthy control subjects were selected at the Blood Donation Unit at the University of São Paulo Medical School.
All the patients and control subjects provided written informed consent for taking blood samples. Approval for the study was obtained from the local Ethics Committee.
DNA extraction
A blood sample of 20 ml was drawn from each participant in the study, and DNA was extracted from leukocytes using the "salting out" protocol 13 .
Genotyping
Genotyping was performed under contract by Prevention Genetics (USA) (www.preventiongenetics.com). The polymorphism investigated was genotyped blind to the individuals' clinical status.
Statistical analysis
The statistical power of the sample was evaluated using the CaTS software (Center for Statistical Genetics, University of Michigan; http://www.sph.umich.edu/csg/ abecasis/CaTS/index.html). A test for deviations from Hardy-Weinberg equilibrium was performed using the HWE program 14 .
The chi-square test was used to investigate possible associations shown by genotypes and alleles with schizophrenia and to assess differences between gender and schizophrenia subtype distributions in both patient and control groups. The analyses were performed using Epi-Info version 6.0.
For all statistical tests, the significance level was set at α<0.05 or 5%.
RESULTS
The sample size power was calculated to be 80% under the following conditions: 200 patients, 400 control subjects, disorder prevalence of 1%, average allelic frequency of 30%, significance level of 0.05 and increased susceptibility towards developing the disorder, of 1.5 for the allele (OR=1.5). If the numbers of patients and control subjects became 245 and 829 respectively, i.e. the number of individuals in the present study, the sample size power would rise to 91%.
For Hardy-Weinberg equilibrium analysis, the actual genotype frequencies were compared with Hardy-Weinbergbased expected genotype frequencies. In both groups (cases: p=0.94; controls: p=0.43), the genotype frequencies were in Hardy-Weinberg equilibrium.
According to our analysis, no statistically significant differences in the distribution of allelic and genotypic frequencies between the groups of patients and controls were observed (Table 1) . Taking into consideration the data suggesting that schizophrenia is a heterogeneous disorder, we also repeated our analyses with division of our sample according to the current most important schizophrenia subtypes (paranoid and disorganized) ( Tables 2 and 3) . Furthermore, the patients and controls were also investigated according to gender, since some studies have suggested that there are differences in the clinical manifestation of schizophrenia according to the patients' gender (Table 4) . Likewise, the samples were also studied in order to ascertain whether homozygosity of the polymorphism investigated could be associated with schizophrenia in our sample (Table 5 ). However, we did not find any significant associations when the analysis was conducted using the phenotypic variables described above. 
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DISCUSSION
In the present investigation, we tested the association between rs165599 A/G COMT genetic polymorphism and schizophrenia in a Brazilian sample of 245 patients (159 males and 86 females) and 829 healthy controls (565 males and 264 females). Despite previous investigations, our study is, to the best of our knowledge, the first association study analyzing this polymorphism in a Brazilian sample of patients with schizophrenia. However, we did not find any association between the polymorphism investigated and schizophrenia.
As mentioned above, we also conducted analyses dividing the sample according to the current most important schizophrenia subtypes: paranoid and disorganized. However, we did not find any significant association when the analysis was conducted using the phenotypic variables described above.
The patients and controls were also investigated according to gender, since some studies have suggested that there may be differences in age of onset and clinical prognosis according to the patients' gender 15 . No difference whatsoever was found. We have tested whether there was any association between homozygosity and schizophrenia. There have been some reports showing associations between homozygosity of other genetic polymorphisms, like Ser9Gly of the dopamine receptor subtype 3 (DRD3), and schizophrenia 16 . This type of association may represent an advantage for heterozygosity, probably because the presence of two different molecular forms of the neurotransmitter receptor, thereby resulting in an increased ability to respond adaptively to variations in the environment, happening either during neural development or in adulthood. However, in our sample, we did not find any such association.
According to our analysis, no statistically significant differences in the distribution of allelic and genotypic frequencies between the groups of patients and controls were observed, even when we stratified the sample according to gender and schizophrenia subtype. Furthermore, no significant association was found when we investigated a possible association between homozygosity of the polymorphism investigated and schizophrenia.
One possible limitation of the present study may relate to population stratification, especially because the Brazilian population is not ethnically homogeneous, which may lead to lower power to detect associations. In populations with highly admixed ethnicity like in Brazil, problems regarding ethnic stratification may be faced. Since physical phenotype in Brazil is not an adequate predictor of genomic ancestry, ethnical matching in case-control studies is rendered difficult 17, 18, 19 . However, the present sample (patients and controls) was in Hardy-Weinberg equilibrium, which indicates that our sample may not have had any important problems regarding population stratification 20 .
In conclusion, the results from the present study do not provide evidence for any association between A/G COMT polymorphism in the non-coding region 3' (165599) and schizophrenia, in the sample investigated. This finding is in accordance with a recent published meta-analysis. However, further studies on this particular polymorphism in relation to schizophrenia are still needed, especially with regard to investigating the different clinical features of the disorder. Investigations in samples with different ethnic backgrounds must be carried out as well.
